MIT Holding reports new revenue streams with up to 52% gross profits. MIT Holding, through its facilitators, is acting as a sub-investigator for Melinta Theraputics, who is the main investigator in the phase 3, multi-center, randomized, double-blind, active controlled study. The purpose of this study is to evaluate the effects of the treatment of patients with complicated bacterial and soft tissue infections.
Walter Drakeford, CEO of MIT Holding stated, “Our test the waters approach to a new revenue stream with these types of margins, are being proven effective with this study. The facilities and employees have met or exceeded all investigative expectations associated with this lucrative and specialized field. This approach has allowed us to streamline our process and provide proof of our capabilities as we look to expand this contract to its maximum commitment, beginning immediately.”
PerClinicaltrials.gov, patients will receive a two to four hour infusion in the blind study at a medical facility. The trial will last for an estimated twelve months and the target enrollment is approximately six hundred and sixty patients (660) treated in the entire trial at multiple facilities throughout the United States, under various sub-investigators. Participants must be 18 years or older and meet the study criteria, you or your doctor may contact the study research staff at ClinicalTrials.gov.
For more information visit www.mitholdingsinc.com
Let us hear your thoughts: MIT Holding, Inc. Message Board